TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

Claude M. Wischik; C. R. Harrington; J. M. D. Storey

doi:10.1016/j.neurobiolaging.2014.01.128

TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

Claude M. Wischik, C. R. Harrington, J. M. D. Storey

Research output: Contribution to journal › Abstract › peer-review

Abstract

There have been 19 phase2/3 clinical trial failures in 15,000 AD subjects to date, all aiming to reduce amyloid pathology. The tau theory has offered an entirely viable alternative conceptual framework, largely ignored for the last 20 years. The filaments of the Alzheimer neurofibrillary tangle are made of a truncated fragment from the repeat domain of tau. This truncated fragment can catalyse the conversion of normal soluble tau into aggregated oligomeric and fibrillary forms which, in turn, can infect neighbouring neurons.

Original language	English
Pages (from-to)	S26
Number of pages	1
Journal	Neurobiology of Aging
Volume	35
Issue number	Suppl. 1
Early online date	14 Mar 2014
DOIs	https://doi.org/10.1016/j.neurobiolaging.2014.01.128
Publication status	Published - Mar 2014
Event	13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy - Geneva, Switzerland Duration: 26 Mar 2014 → 29 Mar 2014

Keywords

tau
methylthioninium
Alzheimer's disease

Access to Document

10.1016/j.neurobiolaging.2014.01.128Licence: Unspecified

Cite this

@article{396f915e14d64f788c5db0d249984dc8,

title = "TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX",

abstract = "There have been 19 phase2/3 clinical trial failures in 15,000 AD subjects to date, all aiming to reduce amyloid pathology. The tau theory has offered an entirely viable alternative conceptual framework, largely ignored for the last 20 years. The filaments of the Alzheimer neurofibrillary tangle are made of a truncated fragment from the repeat domain of tau. This truncated fragment can catalyse the conversion of normal soluble tau into aggregated oligomeric and fibrillary forms which, in turn, can infect neighbouring neurons.",

keywords = "tau, methylthioninium, Alzheimer's disease",

author = "Wischik, {Claude M.} and Harrington, {C. R.} and Storey, {J. M. D.}",

year = "2014",

month = mar,

doi = "10.1016/j.neurobiolaging.2014.01.128",

language = "English",

volume = "35",

pages = "S26",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",

number = "Suppl. 1",

note = "13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy ; Conference date: 26-03-2014 Through 29-03-2014",

}

TY - JOUR

T1 - TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

AU - Wischik, Claude M.

AU - Harrington, C. R.

AU - Storey, J. M. D.

PY - 2014/3

Y1 - 2014/3

N2 - There have been 19 phase2/3 clinical trial failures in 15,000 AD subjects to date, all aiming to reduce amyloid pathology. The tau theory has offered an entirely viable alternative conceptual framework, largely ignored for the last 20 years. The filaments of the Alzheimer neurofibrillary tangle are made of a truncated fragment from the repeat domain of tau. This truncated fragment can catalyse the conversion of normal soluble tau into aggregated oligomeric and fibrillary forms which, in turn, can infect neighbouring neurons.

AB - There have been 19 phase2/3 clinical trial failures in 15,000 AD subjects to date, all aiming to reduce amyloid pathology. The tau theory has offered an entirely viable alternative conceptual framework, largely ignored for the last 20 years. The filaments of the Alzheimer neurofibrillary tangle are made of a truncated fragment from the repeat domain of tau. This truncated fragment can catalyse the conversion of normal soluble tau into aggregated oligomeric and fibrillary forms which, in turn, can infect neighbouring neurons.

KW - tau

KW - methylthioninium

KW - Alzheimer's disease

U2 - 10.1016/j.neurobiolaging.2014.01.128

DO - 10.1016/j.neurobiolaging.2014.01.128

M3 - Abstract

SN - 0197-4580

VL - 35

SP - S26

JO - Neurobiology of Aging

JF - Neurobiology of Aging

IS - Suppl. 1

T2 - 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy

Y2 - 26 March 2014 through 29 March 2014

ER -

TauRx global phase 3 trial in Alzheimer's disease with tau aggregation inhibitor LMTX

Abstract

Keywords

Access to Document

Fingerprint

Cite this